Page 4 - Mark Bleackley News Today

/PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (Incannex or the Company) a clinical-stage pharmaceutical company developing unique...

Australia's Incannex (ASX: IHL) has been given the go-ahead for a clinical trial involving a formulation containing CBD and HCQ.

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has received ethics approval from the Bellberry Human Research Ethics Committee (HREC) to start the phase 1...

Highlights: Bellberry human research ethics committee approved the phase 1 clinical trial investigating safety and pharmacokinetics of IHL-675A on July 20,...

Incannex Healthcare (ASX: IHL) has collared ethics approval, which was the final regulatory hurdle before starting a phase 1 clinical trial of its multi-use anti-inflammatory drug IHL-675A.

The clinical trial assessed three doses of IHL-42X at reducing the AHI in patients with OSA, as well as collected safety data.

Highlights: IHL-42X reduced primary endpoint apnoea hypopnea index relative to baseline at all three doses that were assessed Low dose IHL-42X exhibited...

Incannex characterized the pre-investigational new drug application (pre-IND) meeting about IHL-42X as “highly constructive.”

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has completed a highly constructive Pre-Investigational New Drug (IND Application meeting with the US Food...

/PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), (Incannex or the Company) a clinical-stage pharmaceutical company developing unique...